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Abstract
Background: Lymphadenectomy is an integral part of the staging system of epithelial ovarian cancer. However,
the extent of lymphadenectomy in the early stages of ovarian cancer is controversial. The objective of this study
was to identify the lymph node involvement in unilateral epithelial ovarian cancer apparently confined to the one
ovary (clinical stage Ia).
Methods: A prospective study of clinical stage I ovarian cancer patients is presented. Patient’s characteristics and
tumor histopathology were the variables evaluated.
Results: Thirty three ovarian cancer patients with intact ovarian capsule were evaluated. Intraoperatively, neither of
the patients had surface involvement, adhesions, ascites or palpable lymph nodes (supposed to be clinical stage
Ia). The mean age of the study group was 55.3 ± 11.8. All patients were surgically staged and have undergone a
systematic pelvic and paraaortic lymphadenectomy. Final surgicopathologic reports revealed capsular involvement
in seven patients (21.2%), contralateral ovarian involvement in two (6%) and omental metastasis in one (3%)
patient. There were two patients (6%) with lymph node involvement. One of the two lymph node metastasis was
solely in paraaortic node and the other metastasis was in ipsilateral pelvic lymph node. Ovarian capsule was intact
in all of the patients with lymph node involvement and the tumor was grade 3.
Conclusion: In clinical stage Ia ovarian cancer patients, there may be a risk of paraaortic and pelvic lymph node
metastasis. Further studies with larger sample size are needed for an exact conclusion.
Background
Epithelial ovarian carcinoma (EOC) is a lethal genital
malignancy [1]. Only one third of cases are diagnosed in
the early stages of the disease. Lymphadenectomy is an
integral part of surgical staging and treatment for ovarian
cancers, and they have a potential role in both staging
and retroperitoneal debulking. Lymphatic node metasta-
sis results in a change from stage I to stage IIIC. 5-year
survival decreases from more than 90% to 20% to 60% if
there lymphatic node metastasis is present and adjuvant
therapy is needed [2-4]. However, there is debate on the
extent of lymphadenectomy, particularly in early staged
unilateral tumors (confined to only one ovary) [5,6].
Despite a detailed history of lymphadenectomies in
scientific literature, there are only a limited number of
reports analyzing this topic [5-7]. Furthermore, they are
all of a retrospective nature and only include a small
number of patients. The staging procedures of these stu-
dies and the extent of lymphadenectomies performed are
also debatable. In this study, we aim to analyze the role
and the extent of systematic lymphadenectomies and the
lymphatic metastatic pattern of unilateral clinical stage Ia
ovarian cancers in a prospective pattern, which is the
first of its kind in available published literature. Since
t h en u m b e ro fs u c hp a t i e n t si sl o w ,t h er e s u l t sw e r e
compared and evaluated with the results found in the
literature.
Methods
Two hundred and ninety-three consecutive patients (n =
293) were operated for primary epithelial ovarian carci-
noma at Hacettepe University Faculty of Medicine,
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any medium, provided the original work is properly cited.between January 2004 to April 2007. Fifty-seven (n = 57)
of these patients (19.4%) were diagnosed with tumors
confined to only one ovary based on both pre-operative
and intra-operative evaluations. All the clinico-patholo-
gical variables of these patients are evaluated by using
SPSS version 13.0.
The presence of the following factors were used as
exclusion criteria for this study (clinical stage Ib and Ic
are excluded):
a) Ruptured capsule (intraoperative or postoperative)
b) Presence of ascites
c) Presence of adhesions with neighboring tissues
d) Presence of gross or suspicious tumor on the sur-
face of the capsule
e) Suspicious tumoral involvement of the contralat-
eral ovary
f) Palpable lymphadenopathy suspicious for tumor
metastasis
g) Presence of other concomitant cancers or cancers
other than primary epithelial ovarian carcinoma
h) Patients incompletely staged at an external medi-
cal center or laparoscopy performed before
admission
i) Patients undergoing fertility sparing surgery.
According to the inclusion criteria, twenty-four (n =
2 4 )p a t i e n t sw e r ee x c l u d e df r o mt h es t u d ya n dt h e
remaining thirty-three (n = 33) patients were eligible for
final analysis.
Patient age, gravida, parity and menopausal status,
initial complaints, pre-operative Ca-125 levels, preopera-
tive ultrasonographic appearence, intraoperative findings
(adhesions, capsular involvement or rupture, tumor bila-
terality, presence of ascites or lymphadenopaties or
tumoral implants) and final pathological reports (maxi-
mal tumor size, presence of tumor on the contralateral
ovary, capsular involvement, involvement of peritoneum
or positive cytology, tumor histology, grade, clinical
stage and the number of resected and metastatic lymph
nodes) were the variables collected and analyzed pro-
spectively in this study.
All patients were subjected to a primary surgical sta-
ging procedure by the same surgical team led by one of
t h ea u t h o r sa n de v a l u a t e db yt h es a m ep a t h o l o g i s t ,
according to the FIGO recommendations. After a midline
vertical incision, peritoneal washings were obtained from
the pelvis, para-colic gutters, and diaphragm and then
submitted for cytology. Multiple peritoneal biopsies from
both suspicious and normal appearing areas were taken,
together with the sampling of the diaphragmatic perito-
neum if it was suspicious. All the peritoneal surfaces and
solid organs were explored by inspection and palpation
including the intestinal mesentery, and biopsies were
taken from multiple sites. A total abdominal hysterect-
omy, bilateral salpingo-oopherectomy, and a total omen-
tectomy were the initial steps of the surgery. After an
adequate examination of the pelvis, a systematic pelvic
and para-aortic lymphadenectomy was undertaken.
A pelvic lymphadenectomy was accomplished by comple-
tely skeletonizing the external iliac vessels and removing
all the nodes around the vessels. The common iliac and
obturator nodes were dissected using blunt and sharp
dissection, and all the tissues above the obturator nerve
were removed. The para-aortic area was exposed just
above the bifurcation. The retroperitoneal space and the
lymph nodes at the bifurcation of the aorta anterior to
the vena cava and below the renal vessels on both sides
were dissected. Resected pelvic nodes were subdivided as
right or left sided. However, para-aortic nodes could not
be subdivided in a similar way due to the en bloc resec-
t i o nt e c h n i q u ew eu s e di nt h ep a r a - a o r t i cr e g i o n .T h e
mean number of resected lymph nodes was 35 (range,
23-74), and the mean number of resected para-aortic
lymph nodes was 10 (range 8-16). Finally, appendec-
tomies were performed for all patients if not previously
performed.
There were no severe complications attributable to the
surgery. There was only one bladder injury. Three patients
had postoperative morbidity: one had an intra-abdominal
infection, one had a deep venous thrombo-embolism and
the other patient had an intestinal obstruction that
required another operation for a bridectomy. The overall
morbidity rate was 12% (4/33). Following the final patho-
logic reports, patients with localized microscopic disease
were accepted as upstaged. All patients except for stage
Ia-Ib grade 1-2 disease received adjuvant combination
chemotherapy (six cycles of paclitaxel plus carboplatin).
Patients with unfavorable tumor histology (clear cell, tran-
sient cell or undifferentiated tumors) also received adju-
vant chemotherapy, regardless of their stage or tumor
grade.
The median follow-up of the patients was 16.1 months
(range 1-37). The follow-up period was evaluated from
the date of the operation to the date of the last follow
up. One patient with clear cell histology developed a
vaginal cuff recurrence shortly after the initial six cycles
of chemotherapy. Recurrent disease was treated with
salvage chemotherapy.
Results
The median age of the patients was 55.3 (range 31-82).
Eleven patients (33.3%) were <50 and twenty-two
patients (66.6%) were ≥50. The preoperative Ca-125
level was ≤35 IU/L in 12 patients (36.4%), between
35-500 in 17 patients (51.5%) and ≥500 in the remaining
four patients (12.1%). Tumor histology was serous in
seven patients (22.1%), mucinous in eight patients
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cell in four patients (12.1%). The remaining nine
patients (26.2%) had rare tumor histology’s (mixed
epithelial type in four, transitional in three, anaplastic in
one and squamous in one). Eleven patients had grade 1
disease (33.0%) while eight patients (24.2%) had grade 2
and fourteen patients (42.4%) had grade 3 disease. Maxi-
mal tumor diameter was <10 cm in eighteen patients
(54.5%) and ≥10 cm in the remaining fifteen patients
(45.5%). Eighteen patients had right ovarian tumor and
remaining 15 had left sided tumors. Clinicopathological
features of patients are shown in Table 1.
All the patients were assumed to have tumors in clini-
cal stage Ia after pre-operative and intra-operative eva-
luations. However, twelve patients (36.2%) were found to
have microscopic metastasis after post-operative patholo-
gical evaluations and therefore had upstaged diseases.
Seven of these upstaged patients (21.2%) had capsular
invasion and were upstaged to Ic. One patient (3.0%) had
microscopic omental metastasis with ovarian capsular
invasion and was upstaged to IIIa. Two patients (6.0%)
had ipsilateral ovarian capsular invasion with contralat-
eral ovarian involvement were upstaged to stage Ic. The
remaining two upstaged patients (6.0%) had lymphatic
metastasis and were classified in stage IIIc disease. Two
patients with capsular invasions had serous histology
(one grade 1 and one grade 3), two had mucinous carci-
noma (grade 1), one had clear cell carcinoma (grade 3),
one had squamous cell (grade 3) and one had mixed ser-
ous and mucinous carcinoma (grade 2). The patient with
omental metastasis had mucinous carcinoma (grade 3).
One patient with contralateral ovarian involvement too
had mucinous carcinoma (grade 2) while other had
serous carcinoma (grade 2). Para-aortic lymph nodes
involvement was seen in one patient (left sided tumor)
and ipsilateral pelvic lymph nodes in another. Therefore,
it was decided that a unilateral pelvic lymphadenectomy
would miss half the lymphatic metastasis. Each patient
was found to have one (n = 1) metastatic lymph node.
Tumor histology was serous and transitional cell in these
two patients with lymphatic metastasis. All patients with
lymphatic metastasis had grade 3 disease. None of these
patients had a capsular invasion or involvement of the
contralateral ovary or positive peritoneal cytology.
Discussion
Lymphadenectomy is a routine part of surgical staging in
epithelial ovarian carcinomas [8]. Despite the vast
amount of data detailing the role and extent of lympha-
denectomies in published literature, there are still many
questions that need to be answered. These debates are
particularly important for unilateral tumors apparently
confined to the ovaries. Questions regarding lymphade-
nectomies include: the limits of lymphadenectomies for
these tumors, the sufficiency of performing a unilateral
pelvic lymphadenectomy, the need to perform a para-
aortic lymphadenectomy for patients and the role of
surgical staging in these patients. These questions are
particularly important if one also considers the morbidity
of lymphadenectomy and staging laparotomy. The state
of patients with unilateral tumors with strict criteria as
mentioned above (clinical stage Ia) is another debate; are
systematic lymphadenectomies really necessary or in
other words, is retroperitoneal metastasis really possible
without any intra-abdominal metastasis? And which
lymph nodes are the first to be metastasized?
There are a limited number of published reports evalu-
ating the role of lymphadenectomies in early staged ovar-
ian cancers [2,5-7,9-20]. All the studies are of a
retrospective nature and usually had small sample sizes.
From these studies, lymphatic metastasis is thought to be
present in about 4-27% of early staged patients
Table 1 Clinico-Pathological Features of patients
Features of Patients Number of patients %
Age
< 50 11 33.3
≥50 22 66.7
Gravida
0 3 9.1
1-3 14 42.4
≥4 16 48.5
Parity
0 3 9.1
1-3 23 69.7
≥4 7 21.2
Pre-operative Ca-125
≤ 35 12 37.5
35-500 17 50
≥500 4 12.5
Menopausal status
Premenopausal 21 63.6
Postmenopausal 12 36.4
Histology
Serous 7 21.2
Musinous 8 24.2
Endometrioid 5 15.2
Other* 13 39.4
Grade
1 11 33.3
2 8 24.2
3 14 42.4
Maximal Tumor Diameter
< 10 cm 18 54.5
≥10 cm 15 45.5
Other*: Clear cell in four, mixed type in four, transitional in three, anaplastic in
one and squamous in one patient.
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tic metastatic rates is mainly related to the type of lympha-
denectomy performed in these studies (sampling vs.
systematic, only pelvic or isolated unilateral pelvic etc.).
Our previous study reported a of 13% including clinical
stage I-II patients [23]. Previous reports were also exces-
sively heterogeneous with respect to analyzed variables
such as substages, grades, tumor histology and extend of
lymphadenectomies so that it was almost impossible to
collect all of these studies under a single Table (Table 2
and 3). Majority of previous studies also included patients
with greater than clinical stage Ia disease [2,7,10].
From these studies, we can conclude that lymphatic
metastasis ranges from around 4-27% of clinical stage I
patients with epithelial ovarian carcinomas. Both pelvic
and para-aortic lymph nodes may be involved in these
early staged patients. The number of studies evaluating
the laterality of lymphatic metastasis is even lower
(Table 3) and contrary to our findings; those studies
found that contralateral pelvic lymphatic metastasis
could be seen in a significant percent of clinical stage I
patients. This was also true for clinical stage Ia patients
(Table 3). All previous literature point a high rate of
contralateral pelvic metastasis and recommends a bilat-
eral pelvic lymphadenectomy except for the study by
Benedetti-Panici et al [6]. They evaluated 35 unilateral
clinical stage I patients. Three patients had a metastasis
on ipsilateral pelvic nodes, and two other patients had
Table 2 Pelvic and paraaortic involvement in early staged patients with epithelial ovarian carcinoma
Author Number of
patients
Number of isolated
Pelvic
LN positive patients
Number of isolated
aortic
LN positive patients
Number of Pelvic and aortic positive
patients
Petru et al. [2] 40 7 1 1
Benedetti Panici et al. [6] 37 3 2 0
Onda et al. [10] 59 3 2 8
Sakai et al. [12] 63 2 2 0
Kanazawa et al. [22] 68 5 5 4
Morrice et al [15] 100 3 13 7
Harter et al [16] 70 0 4 4
Total 437 23 (%5.2) 29 (%6.6) 24 (%5.5)
Table 3 Previous studies evaluating the contralateral pelvic and paraaortic lymphatic metastasis presenting in
unilateral clinical stage I or stage Ia epithelial ovarian carcinoma patients (stage Ia patients are bolded and ipsilateral
pelvic metastasis are not included.)
Author Description of Study and
Stages
Tumor Laterality Reported Histology and Grade (Gr) CPLN or PA Met* n
Walter J. [5] Ia
(case report)
Left (Ia) Anaplastic, Gr3 Right paraaortic + right pelvic 1
Onda [10] 7 out of 33 Stage I patients
have lymphatic metastasis. 6
have unilateral tumor.
Left Not defined Bilateral pelvic+PA 1
Right Right PA 1
Right Right pelvic+Right PA 1
Right Left pelvic+Bilateral PA 1
Cass [10] 96 unilateral stage I patients
with unilateral or bilateral
pelvic paraortic
lymphadenectomy are
evaluated. 14 of these 96
had lymphatic metastasis.
Right Gr3 Left PA 1
Right Gr3 Left pelvic 1
Left Gr3 Right PA +Right pelvic 1
Left Gr3 Bilateral pelvic 1
Right Gr3 Bilateral pelvic 1
Right Gr3 Right PA 4
Left Gr3 Left PA 2
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ipsilateral lymph node dissection to be appropriate for
staging and therapeutic purposes [6].
Tumor grades were not reported homogeneously in all
reports. Among the reported cases, majority of the
lymphatic metastasis was seen in high grade (grade 3)
tumors or in unfavorable tumor histologies (transitional,
clear cell etc.). However, there were also reports of low
grade serous tumors with lymphatic metastasis (Table 3).
In our report, also two patients with lymphatic metastasis
Table 3 Previous studies evaluating the contralateral pelvic and paraaortic lymphatic metastasis presenting in unilat-
eral clinical stage I or stage Ia epithelial ovarian carcinoma patients (stage Ia patients are bolded and ipsilateral pelvic
metastasis are not included.) (Continued)
Petru [2] 9 out of 40 Stage I patients
had lymphatic metastasis. 6
out of 9 patients had
unilateral tumors.
Not defined Not defined Contralateral pelvic 1
Pelvic+paraaortic 1
Negishi[9] 8 out of 123 stage I patients
had lymphatic metastasis.
One patient was stage Ia.
Right (Ia) Clear cell (Both) Right paraaortic 2
Left Clear cell (Both) Bilateral PA 2
Left Mucinous (grade ?) Bilateral pelvic and PA 1
Left Clear Left PA 1
Left Mucinous Left PA 1
Left Serous Left PA 1
Sakuragi [13] 4 out of 78 Stage I patients
had lymphatic metastasis.
One patient out of 31 Stage
Ia had lymphatic metastasis.
Right (Ia) Clear cell Gr1 Right PA 1
Left Clear/Mucinous Gr2 Left PA 2
Left Clear cell Gr1 Bilateral PA 1
Morrice [15] 8 out of 60 stage Ia patients
had lymphatic metastasis.
Not defined Gr2:4 Contralateral PA 1
Not defined Gr3:3 Ipsilateral PA 5
Ipsilateral PA+Pelvic 1
Baiocchi, [20] 32 out of 242 Stage I
patients had lymphatic
metastasis. 24 out of 32 was
in Stage Ia. Total number of
stage Ia was 215.
Right Overall distribution Left pelvic 1
Right of grades among Left PA 2
Right patients with Bilateral pelvic+PA 3
Right lymphatic metastasis Right PA 5
Right was as follows: Right pelvic+PA 2
Left Borderline: 7 Left PA 4
Gr1: 3
Gr2: 6
Gr3: 15
Undefined: 1
Suzuki [14] 5 out of 47 Stage I patients
had lymphatic metastasis. 18
patients had Stage Ia
disease.
Not defined Ia Clear cell Gr2 Contralateral pelvic 1
Not defined Serous Gr1 Contralateral pelvic 1
Not defined Serous Gr2 Ipsilateral pelvic+PA 1
Not defined Serous Gr2 PA 1
Not defined Serous Gr1 Ipsilateral suprainguinal 1
This Study 2 out of 33 stage Ia patients
had lymphatic metastasis
Left Transitional Gr3 PA 1
* Contalateral Pelvic or Paraaortic Lymph Node Metastasis in Stage I Epithelial Ovarian Carcinoma.
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tumor histology (transitional cell). An accurate frozen
analysis may direct the physicians to allocate patients for
systematic lymphadenectomy.
This report is unique in that it is the first prospective
study evaluating this topic. All the patients had undergone
a full surgical staging with systematic bilateral pelvic and
para-aortic lymphadenectomies. Our results were similar
to previous reports, when one considers the overall rates
of upstaging (36.2%), rates of lymphatic upstage (6%) and
the localizations of lymphatic metastasis (pelvic and para-
aortic regions were involved) [2,4,5,7,9-20]. And combined
with the previous available data (Table 2 and 3), this study
prospectively shows the necessity of a systematic lympha-
denectomy including paraaortic region, even in clinical
stage Ia low grade patients.
Conclusion
In clinical stage Ia ovarian cancer patients, there may be
a risk of paraaortic and pelvic lymph node metastasis.
Further studies with larger sample size are needed for
an exact conclusion. Currently, considering with the
previous literature (Table 2, 3); a systematic bilateral
pelvic and paraaortic lymphadenectomy should be the
state of art for clinical stage Ia patients.
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